Difficult to Diagnose Cutaneous Melanoma in a Patient with BAP1 Tumor Predisposition Syndrome

Int J Surg Pathol. 2023 Oct;31(7):1398-1402. doi: 10.1177/10668969231152579. Epub 2023 Feb 19.

Abstract

BRCA1-associated protein 1 (BAP1)-inactivated melanomas can occur sporadically or in germline contexts, particularly in recently recognized BAP1-tumor predisposition syndrome. Diagnosis represents a clinical and histopathological challenge, requiring comprehensive analysis of morphology and sometimes molecular analysis in addition to immunohistochemistry. We report a BAP1-inactivated cutaneous melanoma initially diagnosed as an atypical Spitz tumor on the auricle in a patient with BAP1-tumor predisposition syndrome. Immunohistochemistry, fluorescence in situ hybridization, and comparative genomic hybridization allowed diagnosis. Cutaneous BAP1-inactivated melanocytic tumors, previously classified as atypical Spitz Nevi, may have a dermal mitotic activity that can resemble melanoma and on the other hand, atypical Spitz tumors are sometimes difficult to differentiate from BAP1-inactivated melanoma. Specific criteria, requiring molecular diagnosis have been proposed in order to support melanoma diagnosis.

Keywords: BAP1-inactivated melanocytic tumor; BAP1-tumor predisposition syndrome; melanoma.

MeSH terms

  • Comparative Genomic Hybridization
  • Humans
  • In Situ Hybridization, Fluorescence
  • Melanoma* / diagnosis
  • Melanoma* / genetics
  • Melanoma* / metabolism
  • Melanoma, Cutaneous Malignant
  • Neoplastic Syndromes, Hereditary*
  • Nevus, Pigmented* / pathology
  • Skin Neoplasms* / diagnosis
  • Skin Neoplasms* / genetics
  • Skin Neoplasms* / metabolism
  • Tumor Suppressor Proteins / genetics
  • Ubiquitin Thiolesterase / genetics

Substances

  • BAP1 protein, human
  • Tumor Suppressor Proteins
  • Ubiquitin Thiolesterase